Clinical study to investigate safety and efficacy on combination of gemcitabine and autologous gamma/delta T cell transfer therapy after resection of pancreatic cancer
Not Applicable
- Conditions
- Pancreatic cancer
- Registration Number
- JPRN-UMIN000000931
- Lead Sponsor
- The University of Tokyo Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who have: - Pulmonary fibrosis or interstitial pneumonia, or their history, or predisposition to them; - Active enteritis, autoimmune diseases, and/or infections; - Other cancers; - Other serious complications; - Continuous systemic administration of steroids.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety
- Secondary Outcome Measures
Name Time Method Relapse rate (1 and 2 years) Relapse free survival Overall survival Survival rate (1 and 2 years) Response of tumor-related markers Immunological responses